No Data
No Data
Sansheng Pharmaceutical (01530.HK) spent HK$4.37 million to buy back 702,500 shares on May 29
Gelonghui, May 29丨Sansheng Pharmaceutical (01530.HK) announced that it spent HK$4.37 million to buy back 702,500 shares on May 29.
3SBio Subsidiary Strikes Key Weight Management Drug Deal
Sansheng Pharmaceutical (01530.HK): Sansheng Mandy and Hanyu Pharmaceutical reached a cooperation agreement on simeglutide injections
Gelonghui, May 28, 丨 Sansheng Pharmaceutical (01530.HK) announced that Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. (“Sansheng Mandi”), a wholly-owned subsidiary of Shenyang Sansheng Pharmaceutical Co., Ltd., a subsidiary of the Company, signed a “Simeglutide Injection Cooperation Agreement” (“Agreement”) with Shenzhen Hanyu Pharmaceutical Co., Ltd. (“Hanyu Pharmaceutical”). According to the agreement, Hanyu Pharmaceutical and Sansheng Mandi will jointly develop, exclusively supply/procure and sell simeglutide injections (weight loss indications) (“simeglutide injections (weight loss indications)”). Sansheng Mandi will agree to Hanyu Pharmaceutical in accordance with the agreement
3SBio Inc. Schedules Annual General Meeting
Both Individual Investors Who Control a Good Portion of 3SBio Inc. (HKG:1530) Along With Institutions Must Be Dismayed After Last Week's 3.5% Decrease
Key Insights 3SBio's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a majority stake in
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
No Data